Caleb Alexander, a drug safety expert with Johns Hopkins Bloomberg School of Public Health, questions why drug trials exclude some patients, putting actual users at an increased risk for adverse drug effects. “Excluding someone who weighs over 250 pounds?” he said. “Come on. That’s one-fifth of America.”

“More robust safety protocols are urgently needed to prevent serious patient safety events in this high-risk population,” concluded another study.

Read the full article here.